Advanced Medical Optics, Inc. (AMO) (NYSE:EYE) announced today the
expiration of the tender offer and consent solicitation (the “Offer”)
for its outstanding 7½% Senior Subordinated Notes due 2017 (the “Notes”)
(CUSIP No. 00763MAN8, ISIN No. US00763MAN83). The Offer expired at
midnight EST on Tuesday, Feb. 24, 2009 (the “Expiration Time”). As of
the Expiration Time, $248,250,000 aggregate principal amount of
Notes, representing approximately 99.3% of the aggregate principal
amount of Notes outstanding, had been validly tendered pursuant to the
Offer and not withdrawn. AMO accepted for payment, and will pay for,
$248,250,000 aggregate principal amount of Notes today (the
“Payment Date”).
Holders who validly tendered their Notes and delivered their related
consents prior to the Expiration Time received the Total Consideration
of $1,155.00 for each $1,000 principal amount of Notes validly tendered
and accepted for payment. In addition, all holders whose Notes were
accepted for payment received accrued and unpaid interest up to, but not
including, the Payment Date.
In addition, pursuant to the Offer, AMO received consents from holders
sufficient to approve the proposed amendments to the indenture governing
the Notes. As a result, AMO and the trustee will enter into a
supplemental indenture containing the proposed amendments to such
indenture.
This press release is for informational purposes only and is not an
offer to purchase, a solicitation of an offer to sell or a solicitation
of a consent with respect to any of the Notes. The tender offer and the
consent solicitation were only made pursuant to the tender offer and the
consent solicitation documents, including the Offer to Purchase that AMO
distributed to holders of Notes. The tender offer and the consent
solicitation were not made to holders of Notes in any jurisdiction in
which the making or acceptance thereof would not be in compliance with
the securities, blue sky or other laws of such jurisdiction.
About Advanced Medical Optics, Inc. (AMO)
AMO is focused on providing the full range of advanced refractive
technologies and support to help eye care professionals deliver optimal
vision and lifestyle experiences to patients of all ages. Products in
the cataract line include monofocal intraocular lenses (IOLs),
phacoemulsification systems, viscoelastics, and related products used in
ocular surgery.
